By: IPP Bureau
Last updated : April 02, 2026 1:58 pm
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Vyome Holdings, Inc., a next-generation inflammation-focused company leveraging the US-India innovation corridor, has announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq.
As of December 31, 2025, the Company reported total cash, cash equivalents and short-term investments of approximately $4.94 million, supplemented by an additional $5.3 million raised in January 2026 through its ATM agreement. This combined liquidity is expected to fund operations through the anticipated VT-1953 pivotal study interim analysis in mid-2027.
On the operating front, R&D expenses stood at $588,258, while G&A expenses were $2,365,565, reflecting both pre- and post-merger activities. The net loss of $10,477,713 was driven primarily by one-time merger and financing-related expenses of about $7.7 million, including non-cash charges tied to these transactions.
The Company also maintains a clean capital structure, with 5,919,337 outstanding common shares and no preferred stock or debt.
This quarter marks Vyome’s first annual reporting period as a listed Nasdaq company. Vyome is a clinical-stage company positioned to accelerate development across immuno-inflammatory and potential orphan indications.
“Vyome is targeting one of the biggest challenges in the world today - inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building our business with a laser focus on shareholder value, whether it’s our capital structure or the development of our assets,” said Krishna Gupta, Chairman of Vyome. “We had a great first fiscal year completion as a public company, thanks to our unique strengths, including expertise in/access to the US-India innovation corridor.
“This annual reporting marks a defining step forward for Vyome. We executed a highly efficient transition to the public markets, spending less cash than expected in 2025 as a public company and strengthening our organization while advancing our lead program,” noted Venkat Nelabhotla, CEO of Vyome. “The promising final Phase 2 results for VT-1953 reinforce the scientific promise of our immuno-inflammation platform. With our disciplined operations, clean capital structure, and world-class team, we are well-positioned to deliver on the milestones ahead and drive long-term value for both shareholders and patients.”
The company submitted an Orphan Drug Designation application to the FDA in January 2026, with FDA interactions on orphan status and pivotal study design expected in Q2 2026. According to an independent valuation analysis commissioned by Vyome and conducted by Destum Partners, the treatment of malodor in malignant fungating wounds (MFW) represents a $2.2 billion addressable pharmacologic market opportunity in the U.S., where no FDA-approved therapy currently exists. If successful, VT-1953 could become the first and only FDA-approved treatment in this space, with a potential valuation of $1 billion following successful Phase 3 completion.
FDA interactions on pivotal study design and orphan drug designation are expected in the second quarter of 2026
Per an independent valuation analysis commissioned by Vyome and conducted by Destum Partners, Inc., treatment of malodor of MFW represents a potential addressable pharmacologic market opportunity of $2.2B in the U.S., with no FDA-approved drug; VT-1953 would be the only FDA approved solution on the market, with a potential valuation of $1B after a successful completion of a Phase 3 study
MFW is a devastating, rare condition affecting 5–14% of advanced cancer patients, often leading to severe emotional and social burden due to an extremely bad smell, which prevents any interaction with family or friends.
The Company previously reported strong preclinical efficacy for VT-1908 eye drops in uveitis models in the third quarter of 2025, reinforcing its promise as a highly needed steroid-sparing candidate in treating uveitis.